Impact of newly developed, next-generation artificial endocrine pancreas

Kambe, Noriko; Kawahito, Shinji; Mita, Naoji; Takaishi, Kazumi; Katayama, Toshiko; Shibata, Yoko; Soga, Tomohiro; Kawano, Hiroaki; Matsuhisa, Munehide; Shimada, Mitsuo; Kitagawa, Tetsuya; Kitahata, Hiroshi

doi:10.2152/jmi.62.41

Cited by 12 publications

(4 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…23 Also referred to as closed-loop system in the literature, this is an emerging treatment option based on using an algorithm that takes into account the continuous glucose monitoring to determine the most appropriate insulin infusion rate needed. 24 The system continuously monitors blood glucose and only sufficient amount of insulin is injected. This provides a better glycaemic control, precise insulin dosing, reduced insulin spikes, and less episodes of hypoglycaemia.…”

Section: Artificial Pancreasmentioning

confidence: 99%

Therapies for Type 1 Diabetes: Current Scenario and Future Perspectives

Pathak

O'Neill

et al. 2019

Clin Med Insights Endocrinol Diabetes

View full text Add to dashboard Cite

Type 1 diabetes (T1D) is caused by autoimmune destruction of insulin-producing β cells located in the endocrine pancreas in areas known as islets of Langerhans. The current standard-of-care for T1D is exogenous insulin replacement therapy. Recent developments in this field include the hybrid closed-loop system for regulated insulin delivery and long-acting insulins. Clinical studies on prediction and prevention of diabetes-associated complications have demonstrated the importance of early treatment and glucose control for reducing the risk of developing diabetic complications. Transplantation of primary islets offers an effective approach for treating patients with T1D. However, this strategy is hampered by challenges such as the limited availability of islets, extensive death of islet cells, and poor vascular engraftment of islets post-transplantation. Accordingly, there are considerable efforts currently underway for enhancing islet transplantation efficiency by harnessing the beneficial actions of stem cells. This review will provide an overview of currently available therapeutic options for T1D, and discuss the growing evidence that supports the use of stem cell approaches to enhance therapeutic outcomes.

show abstract

Section: Artificial Pancreasmentioning

confidence: 99%

Therapies for Type 1 Diabetes: Current Scenario and Future Perspectives

Pathak

O'Neill

et al. 2019

Clin Med Insights Endocrinol Diabetes

View full text Add to dashboard Cite

show abstract

“…[14] дала на-чало разработке ИПЖ с замкнутым контуром на ос-нове внутривенной (ВВ) инфузии инсулина и глюкозы и ВВ-измерения гликемии. В 1977 г. появилось первое коммерческое стационарное устройство для контроля гликемии Biostator [15], затем другая стационарная си-стема -Nikkiso STG-22 [16], используемая в Японии (в настоящее время вместо STG-22 используют ее усо-вершенствованную версию STG-55) [17]. Несмотря на то, что Biostator и STG-55 широко доступны в условиях стационара, они не рекомендованы для амбулаторного использования из-за больших размеров и несовмести-мости с повседневной жизнью пациентов.…”

Section: ипж и внутривенная инфузия инсулинаunclassified

Intraperitoneal insulin infusion: on the way to the artificial pancreas

et al. 2015

View full text Add to dashboard Cite

Creating an "artificial pancreas" (a "closed loop" insulin pump, with self-adjusting insulin abilities, based on real time continuous glucose monitoring data) – is one of the most actual medical challenges of modern engineering and cybernetics.Artificial pancreas (AP) prototypes based on wearable insulin pump with subcutaneous insulin delivery are still problematic, mainly because of slow insulin pharmacokinetics. Intravenous insulin infusion via AP allows effectively maintain euglycaemia for inpatients, due to insulin pharmacokinetics and pharmacodynamics advantages. Unfortunately, it can’t be used for outpatients. Intraperitoneal insulin infusion is still relatively infrequently used in the world, but it is a promising alternative, compared to both previous methods due to a physiological action profile, fast insulin pharmacokinetics, relatively better safety and availability for outpatient usage.The purpose of this review is to describe the intraperitoneal insulin infusion features for diabetes patients at a point of AP creation perspectives.

show abstract

“…The pharmacokinetic and pharmacodynamic effects of antidiabetic drugs are usually characterized with the glucose clamp technique: Blood glucose concentrations (BG) are kept as closely as possible (“clamped”) at a predefined target level by means of variable glucose infusion rates (GIR) which reflect the metabolic effects of the drug under investigation. 1 In automated glucose clamps with devices like the Biostator (Life Sciences Instruments, Elkhart, IN, USA), 2 the STG-22/STG-55 (Nikkiso Co, Tokyo, Japan), 3 or ClampArt® (Profil, Neuss, Germany), 4 BG is measured continuously and the GIR is calculated with an implemented algorithm every minute.…”

mentioning

confidence: 99%

Considering Blood Dilution improves the Precision of Continuous Whole Blood Glucose Measurements

Benesch

Kuhlenkötter

Heise

2018

J Diabetes Sci Technol

View full text Add to dashboard Cite

Background: One major advantage of automated over manual clamps are continuous measurements of blood glucose concentrations (BG) allowing frequent adaptations in glucose infusion rates (GIR). However, BG measurements might be affected by changes in blood dilution. ClampArt®, a modern automated clamp device, corrects BG measurements for blood dilution, but the impact of this correction is unclear. Methods: The authors performed a retrospective analysis of BG during glucose clamps comparing values with a fixed dilution factor with those corrected for the actual blood dilution. Results: Clamp quality substantially improved with the consideration of blood dilution: Mean accuracy fell from 8.1% ± 2.9% to 4.1% ± 0.8%, precision improved from 9.6 ± 3.6 mg/dl to 3.7 ± 1.3 mg/dl and control deviation from −2.6 ± 4.2 mg/dl to 0.2 ± 0.2 mg/dl. Conclusions: Correcting continuous BG measurements for blood dilution significantly increases BG measurement and clamp quality.

show abstract

Impact of newly developed, next-generation artificial endocrine pancreas

Cited by 12 publications

References 16 publications

Therapies for Type 1 Diabetes: Current Scenario and Future Perspectives

Therapies for Type 1 Diabetes: Current Scenario and Future Perspectives

Intraperitoneal insulin infusion: on the way to the artificial pancreas

Considering Blood Dilution improves the Precision of Continuous Whole Blood Glucose Measurements

Contact Info

Product

Resources

About